Novartis Net Profit Falls 57% --Update
January 27 2016 - 3:01AM
Dow Jones News
By John Letzing and Denise Roland
ZURICH-- Novartis AG said it would revamp its ailing eye-care
unit and has replaced its head after the Swiss drugs giant reported
a 57% drop in net profit for the fourth quarter as the business
dragged on its results.
Basel-based Novartis said on Wednesday that net income fell to
roughly $1.05 billion in the quarter ended in December, compared
with about $2.45 billion in the same period a year earlier.
Revenue dipped 4% to roughly $12.52 billion, the company said.
Core net income, which strips out one-time events such as
impairments or gains, fell 5% to $2.7 billion, Novartis said.
Analysts had expected revenue of $12.7 billion and core net
income of $2.7 billion.
Novartis cited a "weak" performance by its Alcon eye-care unit
in the period.
The company said it has replaced the head of Alcon, by hiring
Mike Ball to step in for Jeff George, who is leaving Novartis. Mr.
Ball is the former chief executive of Hospira.
Mr. George "had a very difficult year at Alcon, obviously,"
Novartis Chief Executive Joseph Jimenez said during a conference
call with reporters.
Mr. Jimenez said that Novartis will narrow Alcon's focus to its
surgical and vision-care businesses, and increase investment in
contact lenses, while transferring the unit's pharmaceuticals
products to Novartis's pharmaceuticals division.
Mr. Jimenez said Novartis will invest about $200 million in a
plan that should boost Alcon's performance, and that he expects the
unit will begin to "return to growth by the end of this year."
In addition, Novartis said it would take steps, including
centralizing manufacturing to reduce costs by $1 billion annually
by 2020. The effort will involve one-time restructuring costs of
about $1.4 billion spread over five years, Novartis said.
For 2016, Mr. Jimenez said Novartis expects revenue and net
profit to be "broadly in line" with results in 2015.
Write to John Letzing at john.letzing@wsj.com and Denise Roland
at Denise.Roland@wsj.com
(END) Dow Jones Newswires
January 27, 2016 02:46 ET (07:46 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2024 to May 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From May 2023 to May 2024